Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of ≥50%: The EMPOWER‐Lung 1 study

BACKGROUND: In the EMPOWER‐Lung 1 trial (ClinicalTrials.gov, NCT03088540), cemiplimab conferred longer survival than platinum‐doublet chemotherapy for advanced non–small cell lung cancer (NSCLC) with programmed cell death‐ligand 1 (PD‐L1) ≥50%. Patient‐reported outcomes were evaluated among trial pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Gümüş, Mahmut, Chen, Chieh‐I, Ivanescu, Cristina, Kilickap, Saadettin, Bondarenko, Igor, Özgüroğlu, Mustafa, Gogishvili, Miranda, Turk, Haci M., Cicin, Irfan, Harnett, James, Mastey, Vera, Naumann, Ulrike, Reaney, Matthew, Konidaris, Gerasimos, Sasane, Medha, Brady, Keri J. S., Li, Siyu, Gullo, Giuseppe, Rietschel, Petra, Sezer, Ahmet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092585/
https://www.ncbi.nlm.nih.gov/pubmed/36308296
http://dx.doi.org/10.1002/cncr.34477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092585/
https://www.ncbi.nlm.nih.gov/pubmed/36308296
http://dx.doi.org/10.1002/cncr.34477

Ejemplares similares